• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies

    Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies

  2. CORRECTING and REPLACING The Vatican Hosts Third International Regenerative Medicine Conference

    CORRECTING and REPLACING The Vatican Hosts Third International Regenerative Medicine Conference

  3. GlaxoSmithKline Start Second Phase Study of Antibody For Inflammatory Osteoarthritis

    GlaxoSmithKline Start Second Phase Study of Antibody For Inflammatory Osteoarthritis

  4. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  5. Common Questions (and Answers) for Uncommon Markets

    Five frequently asked questions for shell-shocked fund investors.

  6. Avoid Medicare Advantage Plans

    GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...

  7. Measuring the Success of Your Dividend Portfolio

    Worry less about beating the benchmark and more about dividend growth and achieving your desired outcomes, says Morningstar's Josh Peters.

  8. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

  9. Peters: Don’t Be Scared by Scotland

    The U.K. will remain a good hunting ground for dividend-paying stocks even if Scotland decides to become independent, says Morningstar's Josh Peters.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.